Ion Beam Applications Sa · EURONEXT:IBAB

Ion Beam Applications Sa — Investor Day (September 2016)

55 slides from Ion Beam Applications Sa's investor day presentation, Sep 26, 2016

  1. Slide 1: Ion Beam Applications Capital Markets Day

    Ion Beam Applications Capital Markets Day Monday 26th September 2016 Olivier Legrain & IBA Management Team investorrelations@iba-group.com

  2. Slide 2: Disclaimer

    Disclaimer This presentation may contain forward-looking statements concerning industry outlook, including growth drivers; the company’s future orders, revenues, backlog, or earnings growth; future financial results; market acceptance of or transition to new products or technology and any statements

  3. Slide 3: Agenda

    Agenda  Business and strategy update  Dosimetry at a glance  The Future of Proton Beam Radiotherapy  North America update  Guidance 3

  4. Slide 4: Business and Strategy Update

    Business and Strategy Update Monday 26th September 2016 Olivier Legrain (CEO) investorrelations@iba-group.com 4

  5. Slide 5: IBA today

    IBA today  IBA is a worldwide technology leader in the field of proton therapy  Most advanced form of cancer treatment with radiation therapy today  Complete offering (Proteus®PLUS and Proteus®ONE)  Global leader in dosimetry and particle accelerators  Three activities with significant market s

  6. Slide 6: IBA stakeholders

    IBA stakeholders Patients & Customers Society Shareholders Environment

  7. Slide 7: Reshaping IBA Culture

    Reshaping IBA Culture New Culture  2-day session where 250 managers learned to concretely change their thinking and behavior  14 culture concepts identified as key in shifting our culture discussed each month with the teams  We are global 250 IBA MANAGERS @ IBA 4.0 USA Belgium China Czech Republi

  8. Slide 8: Expansion Strategy and CAPEX

    Expansion Strategy and CAPEX  Recruitment – 400 engineers and related staff to increase headcount from 1,200 to 1,600 in the next 12 months – 50% in Belgium, remainder in the USA, Europe and Asia  206 already identified  CAPEX – scale-up program to increase capacity including investment in produc

  9. Slide 9: Leading the install base - Market shares in systems

    Leading the install base - Market shares in systems Total: 93 centers IBA Varian Hitachi SHI MELCO Mevion ProTom ProNova AVO 47% 16% 12% 6% 4% 10% 2% 1% 1% 9

  10. Slide 10: Leading the install base - Market shares in rooms

    Leading the install base - Market shares in rooms Total: 235 rooms IBA Varian Hitachi SHI MELCO Mevion ProTom ProNova AVO 47% 21% 15% 5% 5% 4% 2% 1% 0% 10

  11. Slide 11: Market shares in rooms by geography

    Market shares in rooms by geography Rooms (YTD) Number of rooms US Number of rooms EMEA + ROW Hitachi 18% 4% 22% IBA 38% IBA IBA 8% Mevion Mevion 58% IBA Protom 4% Varian 48% Varian Number of rooms Japan Number of rooms - Rest of APAC 2% AVO 15% 13% 21% Hitachi Hitachi 31% IBA 9% IBA 6% 7% MELCO IBA

  12. Slide 12: Drivers for Growth

    DRIVERS FOR GROWTH

  13. Slide 13: Growing recognition of proton therapy clinical advantages

    Growing recognition of proton therapy clinical advantages Oct. 2015 data from a leading center in the US 13 12

  14. Slide 14: Strategy: Grow market from 1% to 20% or more

    Strategy Grow market from 1% to 20% or more Maintain or improve market share 14

  15. Slide 15: Grow market from 1% to 20% or more

    Strategy Grow market from 1% to 20% or more Increase clinical Reduce cost of modality relevance Trials/ Adaptive Hypofrac publicati Equipment/set up Operational costs tionation ons Production Energy Software Imaging Design Building Maintenance Staffing set up consumption 15

  16. Slide 16: Maintain or improve market share

    Strategy Maintain or improve market share Go to market Leverage on other IBA expertises Partnerships Regionalization Dosimetry Other Accelerators 16

  17. Slide 17: Increasing clinical relevance of proton therapy

    Increasing clinical relevance of proton therapy  IBA strategy  Support Focus groups Cumulative number of PT publications 3000  Pediatric  Lung  Head & Neck 2500  Radio-biologic effect 2000  Publish White Papers  PT in Oncology  Treating pediatric tumors with PT 1500 Publications  + GI, H&N

  18. Slide 18: Product strategy overview

    Product strategy overview  Integration  Workflow  Adaptive  Imaging  Cost 18

  19. Slide 19: Excellence in Proton Therapy: Integration

    Excellence in Proton Therapy : Integration TPS/OIS: Open Vendor Strategy (freedom to choose according to your need) Treatment Planning Oncology Information System Proton Treatment delivery System  Xio (Elekta) : 12 centers  Mosaiq (Elekta) : 20 centers  IBA  Eclipse (Varian) : 7 centers  Aria (

  20. Slide 20: Patient throughput – integration - efficiency

    Patient throughput – integration - efficiency WIRELESS SMART 20

  21. Slide 21: And more… with Philips Ambient experience

    And more… with Philips Ambient experience 21

  22. Slide 22: Focus on Online Adaptive Workflow

    Focus on Online Adaptive Workflow In-Room imaging 22

  23. Slide 23: Strategic partnerships in adaptive therapy

    Strategic partnerships in adaptive therapy Step up collaboration in adaptive proton therapy planning New alliance to offer a unique integrated comprehensive solution to advance personalized cancer care for adaptative proton therapy Joint offering of unique proton therapy solutions Ambient Experience

  24. Slide 24: Adaptive Therapy - Open innovative program

    Adaptive Therapy - Open innovative program PATh  Open innovation program, focused on Proton Adaptive Therapy Leading the PATh Launch campaign + landing website (.org) Open PATh  Gateway towards PATh Forum  Discussion platform Other initiatives open-source software to come… for opinion leaders ini

  25. Slide 25: Adaptive therapy: CBCT and In-Room CT

    Adaptive therapy : CBCT and In-Room CT CBCT Penn Medicine, USA In-Room CT, Trento, Italy 25

  26. Slide 26: Adaptive therapy – real time monitoring

    Adaptive therapy – real time monitoring Two prototypes in clinical use: Europe and USA 26

  27. Slide 27: Organ motion management

    Organ motion management Planning optimization 4D CBCT Breath-hold (<10s) Plan Imaging Treat 27

  28. Slide 28: Motion Management: Today

    Motion Management : Today Fast PBS Repainting Dual Spot Size Gating Interface Several centers start to treat moving tumors with PBS 28

  29. Slide 29: Reduce cost of the set up: Proteus One

    Reduce cost of the set up  Proteus One  FDA cleared  CE marked  Treating patients in 2 sites  Shonin filed in Japan 29

  30. Slide 30: Turnkey Building Solution

    Turnkey Building Solution PRAVIDA BAU EUROPEAN GMBH PARTNERSHIP  RISK FREE : Proven Method and Verified Design  FASTER : 4 – 6 months gain on construction  ENVIRONMENTALLY FRIENDLY : Low activation 30

  31. Slide 31: Maximum system availability guaranteed

    Maximum system availability guaranteed Reliability  2015 Availability Uptime above 98% Design 100% 80% Certified PT 60% Experts 40% 20% 0% Remote Maintenance 31

  32. Slide 32: What's next

    What’s next

  33. Slide 33: Being ready for a next potential move!

    Being ready for a next potential move ! 40 years 20 years ? ??? years 33

  34. Slide 34: IBA Dosimetry at a Glance

    IBA Dosimetry at a Glance Frédéric Genin (Chief Marketing Officer Proton Therapy) | communication@iba-group.com

  35. Slide 35: Online Treatment Monitoring (Linac)

    Online Treatment Monitoring (Linac) 1 2 3 Online Measurement Instant Verification 3D Patient Dose Analysis 35

  36. Slide 36: From System Installation to Patient QA

    From System Installation to Patient QA Blue Phantom² MatriXXPT Installation Commissioning Machine QA Patient QA 36

  37. Slide 37: From System Installation to Patient QA

    From System Installation to Patient QA Blue Phantom² MatriXXPT Installation Commissioning Machine QA Patient QA 37

  38. Slide 38: The key to the future of IBA Dosimetry

    The key to the future of IBA Dosimetry Patients 38

  39. Slide 39: myQA Cloud

    my QA Cloud Deinoulon!) Trend Anayysis Mean My MQA Cloud Portal StdDev Variance id ft Median Skewness Range Min , Max ‘Own Results 0.0% 7. 97.4 104.9 101.18 1.54 », 2.38 , 101.29 Overall Results 99.98 ., 1.50 2.25 100.00 ., a00.21 aoa Results 30221 221 0421 Distribution | Trend Analysis 105.44 % 104

  40. Slide 40: IBA North America

    IBA North America Capital Markets Day, ASTRO 2016 Beth Klein (President, North America PT) | beth.klein@iba-group.com

  41. Slide 41: IBA Proton Therapy North America

    IBA Proton Therapy North America All Proton Therapy Activities co-located in Reston :  Sales, Marketing, Sales Support, Product Specialists  Project management, Install Teams  Service Delivery, Operations  Installed Base Upgrades  EHS, Legal, Information Technology  Finance  Research and Deve

  42. Slide 42: Projected PT Market Growth/Opportunity N. America

    Projected PT Market Growth/Opportunity N. America PT Rooms Sold 1996-2016 120 100 80 60 40 20 0 How can we accelerate to MAX POTENTIAL? 42

  43. Slide 43: High Level Market Drivers

    High Level Market Drivers ACCELERATORS BRAKES  Competition fueling demand (fear of losing  Reimbursement share)  Election year anxiety  Turf war is on - defensive & offensive strategies  Value Paradigm/MACR impact?  Fear of losing patients/revenue > fear of PT  Private Payers not paying; no p

  44. Slide 44: IBA NAM PT Market Share Snapshot 2016

    IBA NAM PT Market Share Snapshot 2016 Single Rooms in Market Market Facilities share Rooms share room multi room facilities facilities IBA 14 44% 44 48% 3 41 Hitachi 5 16% 20 22% 0 20 Mevion 7 22% 7 8% 7 0 Protom 2 6% 4 4% 1 3 Varian 4 12% 16 18% 0 16 32 91 Includes  Installed Base Number of rooms

  45. Slide 45: Proton Therapy Installed Base North America

    Proton Therapy Installed Base North America IBA (14) Mevion (7) Varian (4) Hitachi (5) Protom (2) 45

  46. Slide 46: IBA NAM PT Top-Down Account Segmentation

    IBA NAM PT Top-Down Account Segmentation ~ 2300 Radiotherapy Facilities in the U.S. Free standing non- Excluding hospital based ~ 1220 Hospital Based RT Centers centers Territory 1 Territory 2 Territory 3 Outreach to Outreach to Outreach to ~ 850 RT Centers with Observers Observers Observers Excludi

  47. Slide 47: Why is IBA successful in PT in North America?

    Why is IBA successful in PT in North America? 1. Experience: 30 years dedicated to PT – Success from Start to Finish 2. NO Obsolescence: proven upgradeability path 3. Execution: 12 months installation – guaranteed 4. Training: comprehensive training program 5. Uptime: demonstrated and proven (97%) 6

  48. Slide 48: Reimbursement Trend Supporting PT Development

    Reimbursement Trend Supporting PT Development Medicare Reimbursement Rate Evolution (Dollars per Fraction) 1600 1400 1200 1000 Dollars per Fraction 800 600 Proton Beam Therapy codes 77522, 77523 and 77525 are included in APC 5625 Level 5 Radiation Therapy. In 2016, the APC was Simple (1F (Compensato

  49. Slide 49: Shift to Value Based Paradigm also supports PT

    Shift to Value Based Paradigm also supports PT What is it?  Shift in Payment from Fee-for-Service Model to Value Based Payment  Value is defined by Quality/Cost  Quality is being defined between providers and CMS  MACR alignment with CMS is key to Congress vote to go forward Why is this signific

  50. Slide 50: Financials and Guidance

    FINANCIALS AND GUIDANCE

  51. Slide 51: Key financials

    Key financials  2015 sales: EUR 270 million (+ 22.6%) ; H1 16: +19,9% ;  REBIT margin 2015 : 10.9% ; H1 16: +20,0%  Backlog of EUR 349 million end H1 16 (+15% vs H1 15). REBIT / Sales and services trends Equipment backlog 51

  52. Slide 52: Guidance – top line

    Guidance – top line  Based on the following elements at H1 2016 :  PT & Other Accelerators equipment backlog of EUR 349 million  PT & Other Accelerators service backlog of EUR 567 million, representing 37 signed contracts of 10 years on average  Dosimetry backlog of EUR 18.3 million  Clear prod

  53. Slide 53: Guidance – REBIT margin & dividend

    Guidance – REBIT margin & dividend  REBIT guidance confirmed :  About 11% in 2016  13 to 15% by 2018  Guidance supported by the balance between :  Economies of scale/operational leverage  Growing importance of Services  Price erosion  Investment in scaling up company production capacity and

  54. Slide 54: Q&A

    Q&A 54

  55. Slide 55: Thank you

    ‘Thank you,

Ion Beam Applications — Investor Day (September 2016) on 6ix